
































































WBC 420/IL2 Crea 0.6nq/dL GGT 28U/A
Ly 18.5% Alb 3.4g/dB ZTT 14.OU
Mon 8.0% FBS 93mg/dB TTT ll.1U
Stab 5.0% CHOL 176mg/dA SeMn叩蜘肋 加
Seg 61.5% TRIG lllmg/dB Alb 60.5%
[0 6.5% CL 10.2mmol/` α1-g1 2.6%
BA 0.5% NA 138.Om ol/& α2-g1 7.8%
RBC 396×10-/JLR K 4.38mmol/A β-gl 8.8%
Hb ll.9g/dA Ca 8.6mg/dB rg1 20.1%
Hct 35.3% CRP 0.lng/dB HBSAg (-)
PLT 21.3×10ソ 〃` AST 21〕/l antl-HCV11(-)
BloodChemLCalFIndings ALT 21U/A TPHA (-)






































































































































Administration of filgrastim in two patients
with drug-induced agranulocytosis. Pharma-
cotherapy, 18, 1347 -1351, 1998.
A case of Parkinson's disease associated
with bromocriptine - induced leukopenia and
throm-bocytopenia
Shingo Takata, Takashi Mifune,
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Norikazu Nishida, Hirofumi Tsugeno,
Kozo Ashida, Yasuhiro Hosaki, Tadashi Yokoi,
Yoshiro Tanizaki, Kenji Niiya 1) and
Mitsune Tanimoto 1)
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1) Second Department of Medicine, Okayama
University Medical School
A 67-year-old woman had been treated for
Parkinson's disease before. She was admitted to
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our hospital for rehabilitation. On admission the
leukocyte count and the platelet count were
normal. But routine blood studies began to
show leukopenia and thrombocytopenia after
administration of bromocriptine. We suspected
drug-induced leukopenia and thrombocytopenia.
After stopping bromocriptine therapy and ad-
ministration of filgrastim, the leukopenia and
the thrombocytopenia disappeared. She devel-
oped leukopenia again after provocation test
with bromocriptine. There are few reports about
bromocriptine-induced leukopenia and thrombo-
cytopenia. To our knowledge, only 2 cases (in-
cluding our case) of bromocriptine-induced
leukopenia have been reported. Bromocriptine
has much data about safety and neuroprotection.
However, we must take care of the safety fully.
